Updated on 3 January 2013
Hopefully the US FDA will complete the review of Merck's New Drug Application (NDA) for ezetimibe and atorvastatin tablets during the first half of 2013
Singapore: US FDA has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine developed by Merck.
Merck expects the FDA's review to be completed during the first half of 2013. Merck is continuing to move forward with planned filings for the ezetimibe and atorvastatin combination tablet in additional countries around the world.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
